SCHEMBL2470655

SCHEMBL2470655

CN(C)CC(=O)N(Cc1ccc(OCC(=O)O)cc1)Cc1csc(-c2ccc(C(=O)NCCCCc3ccccc3)cc2)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.49
TP53 P04637 4/20 0.49
ALDH1A1 P00352 3/20 0.48
POLB P06746 3/20 0.46
SLC2A1 P11166 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.42
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42
SIGMAR1 Q99720 3/20 0.42
TMEM97 Q5BJF2 2/20 0.42
PPARA Q07869 1/20 0.42
KDM4E B2RXH2 1/20 0.41
HPGD P15428 1/20 0.41
AGTR1 P30556 1/20 0.41
HTT P42858 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
LMNA P02545 1/20 0.41
LPAR1 Q92633 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2471479 0.93 MAPT (0.49) MAPTTP53ALDH1A1POLBSMN1; SMN2
SCHEMBL1734794 0.90 MAPT (0.53) MAPTTP53ALDH1A1POLBSMN1; SMN2
SCHEMBL2471727 0.87 TP53 (0.50) MAPTTP53ALDH1A1POLBSMN1; SMN2
SCHEMBL2469743 0.87 MAPT (0.46) MAPTTP53ALDH1A1POLBSMN1; SMN2
SCHEMBL2469736 0.87 MAPT (0.46) MAPTTP53ALDH1A1POLBSMN1; SMN2
SCHEMBL2473831 0.86 MAPT (0.45) MAPTTP53ALDH1A1POLBSMN1; SMN2
SCHEMBL2472568 0.85 TP53 (0.49) MAPTTP53ALDH1A1POLBSLC2A1
SCHEMBL5100829 0.84 PTPN1 (0.44) MAPTTP53ALDH1A1POLBSMN1; SMN2
SCHEMBL2466069 0.82 ALDH1A1 (0.47) MAPTTP53ALDH1A1POLBSMN1; SMN2
SCHEMBL2468211 0.80 ALDH1A1 (0.49) MAPTTP53ALDH1A1SMN1; SMN2PPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7365225-B2 Aryl dicarboxamides LABORATOIRES SERONO SA (CH) 2008-04-29 US claimed
EP-1656139-A1 ARYL DICARBOXAMIDES Applied Research Systems ARS Holding N.V. (AN) 2006-05-17 EP claimed
WO-2005011685-A1 ARYL DICARBOXAMIDES APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) 2005-02-10 WO claimed
EP-1656139-B1 ARYL DICARBOXAMIDES MERCK SERONO SA (CH) 2011-10-05 EP disclosed
US-7365225-B2 Aryl dicarboxamides LABORATOIRES SERONO SA (CH) 2008-04-29 US disclosed
US-7365225-B2 Aryl dicarboxamides LABORATOIRES SERONO SA (CH) 2008-04-29 US disclosed
US-7365225-B2 Aryl dicarboxamides LABORATOIRES SERONO SA (CH) 2008-04-29 US disclosed
US-20060189583-A1 Aryl dicarboxamides MERCK SERONO SA (CH) 2006-08-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189583-A1 Aryl dicarboxamides GPR119, PTPRS, ECHS1 MAPT 4883/4885TP53 1795/4885ALDH1A1 1704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.